Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × pertuzumab × 90 days × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Neoplasms 5 Neoplasm Metastasis 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Inflammatory Breast Neoplasms 2 HER2-positive Early Breast Cancer 2 HER2-positive Breast Cancer 2 Endometrial Neoplasms 2 Colonic Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Solid Cancer 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Patient Preference 1 Pathologic Complete Response 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Malignant Solid Neoplasm 1 Liver Neoplasms 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early-stage Breast Cancer 1 Gastrointestinal Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1

Interventions

fludarabine phosphate 2 fludarabine 2 Whole-Body Irradiation 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Cyclophosphamide 2 Cisplatin 2 Busulfan 2 trametinib 1 pralsetinib 1 ponatinib 1 pembrolizumab 1 durvalumab 1 dabrafenib 1 Radiotherapy, Intensity-Modulated 1 Pemetrexed 1 Paclitaxel 1 Nimorazole 1 Immunotherapy 1 Gemcitabine 1 Carboplatin 1 Bone Marrow Transplantation 1 Biopsy 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡